Congress Ambassadors


The World Healthcare Congress Europe Ambassador programme recognises people who have worked with us to amplify the importance of the topics being discussed at WHCE 2019. The ambassadors are experts within their field who are supporting health and social care innovation to drive change to ultimately ensure the future sustainability of healthcare systems.

Steve Tremitiere

Founder and CEO of GrayHare Ventures and Chief Development Officer for Briovation

Steve Tremitiere is Founder and CEO of GrayHare Ventures and the Chief Development Officer for Briovation.  Steve has 30 years of experience in strategic business development across a wide range of industries with focus on health and technology, and has an extensive background working with startups and new business initiatives.  He is currently engaged with a large national health system to launch a highly innovative population health initiative, and also leads Briovation’s development efforts as it looks to transform health care investing. In addition to his professional work he serves on advisory boards for a number of social impact organizations including Esther Dyson’s Wellville Initiative, EveryoneOn, Village Capital, Social Innovations Lab and the WISER Girls Initiative in Kenya.

Cellen M.Kigin


Colleen M. Kigin, PT, DPT, FAPTA presently serves as a Clinical Professor and Chair of the Scholarship and Endowment Board for the University of Colorado Physical Therapy Program, University of Colorado School of Medicine, Denver, Colorado, USA. From 2014-2015, Dr. Kigin served as a consultant to the University of Manchester, Manchester Academic Health Science Centre, UK and for Strategic Analysis, assigned to the Defense Advance Research Projects Agency (DARPA) for the US military, focused on healthcare innovation. Prior to this, she served as Chief of Staff for the Center of Integration of Medicine and Innovative Technology, a 12 institution consortium developing innovative solutions to healthcare problems.

In 1994, she joined the newly formed Partners HealthCare System in Boston, Massachusetts, coordinating the system’s cost reduction efforts from 1994 to 1998. Dr. Kigin previously served as the Director of Physical Therapy Services at Massachusetts General Hospital, and Assistant Professor at the MGH Institute of Health Professions (MGH IHP) Dr. Kigin earned a Bachelor of Science in Physical Therapy at the University of Colorado, Master of Science at Boston University, Master in Public Administration from the Harvard Kennedy School of Government and Doctor in Physical Therapy from the MGH IHP.

Prof Nikolaos Strimpakos

Department of Physiotherapy, TEI of Sterea Ellada, Lamia, Greece

Dr. Nikolaos Strimpakos is a Professor of Physiotherapy, in Physiotherapy Department, TEI of Sterea Ellada and holds Honorary contracts as Research Associate from the University of Manchester and from the University of Athens. He has an MSc in Physiotherapy (2000) and a PhD in Rehabilitation Science (2004) from University of Manchester with specific interest in musculoskeletal assessment and rehabilitation. He has attended numerous post-graduate courses and seminars and he has published more than 40 peer reviewed papers in international journals having up to now more than 1400 citations while he has been principal investigator or member of the main research team in several research proposals the last years ( Dr. Strimpakos is currently Vice-Rector of TEI of Sterea Ellada, Director of the Center of Technological Research of Central Greece and Head of MSc in Advanced Physiotherapy. He is also a member of Education Matters Working Group and Foundation Working Group of the World Confe

deration for Physical Therapy-European Region (WCPT-ER).

Prof Mark Lawler

Chair in Translational Cancer Genomics and Dean of Education in the Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast

Mark has published over 180 papers in international peer review journals, including key papers in the highest impact journals (New Engl J Medicine, Lancet, Nature Medicine, Lancet Oncology, Cancer DiscoveryNature Comms, Gut etc). He has been successful in attracting over £20M of research funding. He is a member of the Board of the European Alliance for Personalised Medicine (EAPM) and developed EAPM’s research strategy. Mark’s work has been recognised by a number of national/international awards including the Vander Molen Prize for Leukaemia Research, the Ely Lilly Prize, the St Lukes Medal for Cancer Research and the Graves Medal for Medical Research.

Mark is Associate Director of Health Data Research Wales-Northern Ireland, one of only 6 substantive sites of Health Data Research UK(HDR-UK), which aims to drive innovative precision medicine and public health approaches through the use of Big Data. He is also national lead for the Cancer Data Research Strategy for HDR-UK. In the wake of the Cambridge Analytica/Facebook scandal, he recently led a pan European group in the publication of a roadmap to restore public trust in health data, published in Lancet Oncology, the premier cancer journal in the world. Mark was co-chair of the Cancer Task Team of the Clinical Working Group of the Global Alliance for Genomics and Health, an international cooperative dedicated to effective and responsible sharing of genomic and clinical data. He has authored a number of key papers including a blueprint for cancer date sharing (Nature Medicine) and a road map/call to action for a Global Cancer Knowledge Network in the New England Journal of Medicine, the top medical journal in the world. He is co-lead of an ambitious proposal to develop a Global Innovation Institute which will include the  One Health Innovation Centre (OHIC), Europe’s  first Health and Agri-Food Informatics Innovation Centre.

Mark is the Queen’s Lead of the £5M Medical Research Council-Cancer Research UK funded Personalised medicine programme Stratified Medicine in Colorectal Cancer Consortium (S:CORT), a UK-wide consortium investigating novel precision medicine approaches in CRC. His international reputation in CRC was instrumental in his leading a Critical Gaps in CRC Research Initiative, recently published in the high impact factor journal Gut; this landmark publication has attracted significant global attention (his podcast had the most “hits” of any article in the journal).

Mark is frequently invited as a guest speaker to international conferences and sits on a number of high level committees at European level including EAPM, the Scientific Board of the European Cancer Patient Coalition and the European Cancer Organisation (ECCO) Oncopolicy Forum

Mark has a strong commitment to patient-centred research/care and to addressing cancer inequalities. He was the architect of the European Cancer Patient’s Bill of Rights (BoR), a catalyst for change and empowerment tool for cancer patients which he launched in the European Parliament on World Cancer Day 2014. The BoR has been adopted across Europe and  led to the 70:35 Vision, 70% survival for all cancer patients in Europe by 2035 which was recently adopted by ECCO, the largest interdisciplinary cancer organisation in Europe. The Bill of Rights recently received The 2018 European Health Award, a prestigious award for partnerships that yield real health impact in Europe and Mark received the award on behalf of this collaborative initiative during the 2018 European Health Forum Gastein, the premier European health policy Conference  . Mark’s advocacy work was instrumental in the recent decision to recommend that boys be included in the national UK HPV vaccination programme.  He is also committed to the provision of optimal pathology and laboratory medicine for citizens in resource-limited settings and was senior author of a recent paper in The Lancet as part of The Lancet Series on Pathology and Laboratory Medicine in Low- and Middle- Income Countries.